Evidence map›Paper›PMID 36530898›Full record

ArticleFrontiers in medicine2022

The impact on the scientific community of the 2018 addendum to the CHCC.

Marzia Caproni, Valentina Ruffo di Calabria, Elena Biancamaria Mariotti, Alice Verdelli, Cristina Aimo, Alberto Corrà, Lavinia Quintarelli, Walter Volpi, Erkan Alpsoy, Cord Sunderkötter

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marzia CaproniImmunopathology and Rare Skin Disease Unit, P.O. Piero Palagi, Azienda USL Toscana Centro, ERN-SKIN Member, University of Florence, Florence, Italy.
Valentina Ruffo di CalabriaSection of Dermatology and Venereology, Department of Health Sciences, University of Florence, Florence, Italy.
Elena Biancamaria MariottiSection of Dermatology and Venereology, Department of Health Sciences, University of Florence, Florence, Italy.
Alice VerdelliSection of Dermatology and Venereology, Azienda USL Toscana Centro, Florence, Italy.
Cristina AimoSection of Dermatology and Venereology, Department of Health Sciences, University of Florence, Florence, Italy.
Alberto CorràSection of Dermatology and Venereology, Department of Health Sciences, University of Florence, Florence, Italy.
Lavinia QuintarelliImmunopathology and Rare Skin Disease Unit, P.O. Piero Palagi, Azienda USL Toscana Centro, ERN-SKIN Member, University of Florence, Florence, Italy.
Walter VolpiSection of Dermatology and Venereology, Azienda USL Toscana Centro, Florence, Italy.
Erkan AlpsoySection of Dermatology and Venereology, Akdeniz University School of Medicine, Antalya, Turkey.
Cord SunderkötterDepartment of Dermatology and Venereology, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, Wittemberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

addendum to Chapel Hill ConsensusChapel Hill Consensus Conferencenomenclatureprovisional definitions of vasculitidesvasculitides

Identifiers

PMID36530898
PMCPMC9751210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.